IMMUNITYBIO, INC. Amortization of Debt Issuance Costs and Discounts
IMMUNITYBIO, INC. (IBRX) reported Amortization of Debt Issuance Costs and Discounts of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-02-23
- IMMUNITYBIO, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. amortization of debt issuance costs and discounts for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- IMMUNITYBIO, INC. amortization of debt issuance costs and discounts for fiscal 2024 was $22.59M, a 46.72% decline from fiscal 2023.
- IMMUNITYBIO, INC. amortization of debt issuance costs and discounts for fiscal 2023 was $42.40M, a 160.39% increase from fiscal 2022.
- IMMUNITYBIO, INC. amortization of debt issuance costs and discounts for fiscal 2022 was $16.28M, a 26161.29% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $5.01M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $5.01M derived: sum of 3 quarters · filed 2026-02-23 | $11.21M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | $5.01M derived: sum of 2 quarters · filed 2026-02-23 | $11.21M derived: sum of 3 quarters · filed 2026-02-23 | $17.04M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | $5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $11.21M derived: sum of 2 quarters · filed 2026-02-23 | $17.04M derived: sum of 3 quarters · filed 2026-02-23 | $22.59M 10-K · filed 2026-02-23 |
| 2024-09-30 | $6.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.03M derived: sum of 2 quarters · filed 2025-11-05 | $17.58M 10-Q · filed 2025-11-05 | $24.70M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $5.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $11.38M 10-Q · filed 2025-08-05 | $18.50M derived: sum of 3 quarters · filed 2026-02-23 | $29.95M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $5.55M 10-Q · filed 2025-05-12 | $12.67M derived: sum of 2 quarters · filed 2026-02-23 | $24.12M derived: sum of 3 quarters · filed 2026-02-23 | $36.41M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $18.57M derived: sum of 2 quarters · filed 2026-02-23 | $30.86M derived: sum of 3 quarters · filed 2026-02-23 | $42.40M 10-K · filed 2026-02-23 |
| 2023-09-30 | $11.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $23.74M derived: sum of 2 quarters · filed 2024-11-12 | $35.28M 10-Q · filed 2024-11-12 | $46.32M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $12.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $23.82M 10-Q · filed 2024-08-12 | $34.86M derived: sum of 3 quarters · filed 2025-03-03 | $39.36M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $11.54M 10-Q · filed 2024-05-09 | $22.58M derived: sum of 2 quarters · filed 2025-03-03 | $27.07M derived: sum of 3 quarters · filed 2025-03-03 | $27.45M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $11.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $15.54M derived: sum of 2 quarters · filed 2025-03-03 | $15.91M derived: sum of 3 quarters · filed 2025-03-03 | $16.28M 10-K · filed 2025-03-03 |
| 2022-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.87M derived: sum of 2 quarters · filed 2023-11-09 | $5.24M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $744.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $370.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $62.00K 10-K · filed 2024-03-19 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |